🇺🇸 FDA
Patent

US 10849917

Antisense-induced exon exclusion in type VII collagen

granted A61KA61K31/70A61P

Quick answer

US patent 10849917 (Antisense-induced exon exclusion in type VII collagen) held by Sarepta Therapeutics, Inc. expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sarepta Therapeutics, Inc.
Grant date
Tue Dec 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K31/70, A61P, A61P17/00